Log in or register
Share on LinkedInShare on LinkedIn

ARTICLE · 15 JULY 2026

Jason Adelstone To Speak On DEA Marijuana Rescheduling Hearing

Harris Sliwoski
Explore more from Harris Sliwoski

The DEA's marijuana rescheduling hearing raises critical questions about the future of cannabis regulation and what Schedule III classification could mean for businesses, investors, and the broader industry. Harris Sliwoski attorney Jason Adelstone joins industry experts to discuss the latest developments from the hearing and the legal and business implications companies should monitor as the federal rescheduling process unfolds.

United StatesCannabis & Hemp
Jason Adelstone
Jason Adelstone
Author LinkedIn connections

1817548a.jpg

The DEA’s marijuana rescheduling hearing continues to raise important questions for cannabis businesses, investors, and the industry as a whole. If you’re trying to keep up with where things stand and what may come next, this upcoming MJBizDaily webinar is worth your time.

Harris Sliwoski attorney Jason Adelstone will join a panel of industry professionals to discuss the latest developments from the hearing, what Schedule III rescheduling could mean in practice, and the legal and business issues companies should be watching as the process moves forward.

Jason regularly advises cannabis businesses on regulatory compliance, licensing, and cross-border matters, and he’ll share his perspective on how these federal developments may affect the industry in the months ahead.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

Register for freeORLog in

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

View source

Related Articles

Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics

Read more about

See more popular content from

Article

The Intoxicating Hemp Products Ban Was Delayed A Month. Now What?

The House has passed a short-term funding bill postponing the federal ban on hemp-derived THC products from November 12th to December 11th. With comprehensive legislation unlikely before the new deadline and competing interests from cannabis sellers, alcohol producers, and state regulators creating policy gridlock, the future of intoxicating hemp products remains uncertain as midterm elections approach.
United StatesCannabis & Hemp
Harris Sliwoski
Harris Sliwoski
Article

IRC Section 280E And Cannabis Tax Planning: Recent Developments And Practical Considerations

The landscape surrounding Section 280E of the Internal Revenue Code continues to evolve with President Trump's Executive Order on medical marijuana rescheduling, advancing litigation in New Mexico Top Organics v. Commissioner, and shifting regulatory signals. Cannabis taxpayers face critical decisions about taking "non-280E" positions on their tax returns while the IRS maintains its enforcement stance and the U.S. Tax Court case addressing common arguments remains pending.
United StatesCannabis & Hemp
Foley Hoag LLP
Foley Hoag LLP
Article

"Marijuana" Rescheduling Delayed, Again. What It Could Mean, And What Comes Next

The DEA's marijuana rescheduling hearing has been unexpectedly stayed following a motion to admit a new GAO report examining agency scheduling procedures. With the proceeding on hold and the medical marijuana Schedule III order facing legal challenges in the D.C. Circuit, the cannabis industry's path to federal tax relief through rescheduling has become increasingly uncertain.
United StatesCannabis & Hemp
Harris Sliwoski
Harris Sliwoski